Intellia Therapeutics finds itself navigating turbulent waters, with its stock price hitting fresh lows as a combination of clinical setbacks and insider sel ...

Acumen Pharmaceuticals is developing ACU193 as the first clinical-stage therapeutic to selectively target toxic soluble amyloid-β oligomers (AβOs), which are an early and persistent driver of ...